Oxford BioMedica plc (OXB) Price Target Increased to GBX 8.70 by Analysts at N+1 Singer
Oxford BioMedica plc (LON:OXB) had its price objective raised by N+1 Singer from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) in a research note issued to investors on Thursday morning. They currently have a hold rating on the biopharmaceutical company’s stock.
OXB has been the topic of several other reports. Shore Capital reiterated a not rated rating on shares of Oxford BioMedica plc in a research report on Thursday, July 13th. Jefferies Group LLC reiterated a buy rating and issued a GBX 13 ($0.17) price target on shares of Oxford BioMedica plc in a research report on Thursday, July 13th.
In other Oxford BioMedica plc news, insider Lorenzo Tallarigo purchased 53,260 shares of the stock in a transaction dated Wednesday, May 24th. The shares were acquired at an average cost of GBX 5 ($0.07) per share, for a total transaction of £2,663 ($3,469.25). Also, insider Peter Nolan bought 249,687 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were purchased at an average price of GBX 8 ($0.10) per share, for a total transaction of £19,974.96 ($26,022.62). Insiders bought 1,011,980 shares of company stock worth $8,448,961 over the last quarter.
Oxford BioMedica plc Company Profile
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with Analyst Ratings Network's FREE daily email newsletter.